Ryuzo Nawada

Impact of body weight on clinical outcomes in cancer patients with low-risk pulmonary embolism receiving rivaroxaban: Insights from the ONCO PE trial.

Journal: Thrombosis research

Published: January 22, 2026

A systematically derived risk model for 3-year all-cause mortality after acute venous thromboembolism.

Journal: Journal of cardiology

Published: December 01, 2025

Utility of simplified PESI score for mid-term mortality risk stratification: Insights from the combined COMMAND-VTE registries.

Journal: Journal of cardiology

Published: November 14, 2025

Associations between heart failure-related quality of life and clinical parameters in patients with hypertrophic cardiomyopathy: a cross-sectional analysis of data from a multicentre Japanese registry.

Journal: BMJ open

Published: November 14, 2025

Impact of stricter lipid control on cardiovascular outcomes in a regional hospital-clinic referral system.

Journal: Journal of cardiology

Published: September 23, 2025

Clinical Outcomes of Anticoagulation Therapy With Direct Oral Anticoagulants or Warfarin in Patients With Atrial Fibrillation and Renal Impairment After Bioprosthetic Valve Replacement.

Journal: Circulation reports

Published: August 12, 2025

Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).

Journal: Circulation

Published: November 18, 2024

Bioprosthetic Valve Positions in Patients With Atrial Fibrillation　- Insights From the BPV-AF Registry.

Journal: Circulation reports

Published: September 18, 2024

CORRIGENDUM: Antithrombotic Therapy for Patients With Atrial Fibrillation and Bioprosthetic Valves　- Real-World Data From the Multicenter, Prospective, Observational BPV-AF Registry.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: August 25, 2024

Long-Term Effects of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention in High-Risk Subgroups.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: August 07, 2024

R2-CHA2DS2-VASc Score for Cardiovascular Event Prediction After Bioprosthetic Valve Replacement　- Subanalysis From the BPV-AF Registry.

Journal: Circulation reports

Published: April 02, 2024

Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism　- A Predetermined Companion Report From the ONCO PE Trial.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: March 10, 2024

Impact of body weight on clinical outcomes in cancer patients with low-risk pulmonary embolism receiving rivaroxaban: Insights from the ONCO PE trial.

Impact of body weight on clinical outcomes in cancer patients with low-risk pulmonary embolism receiving rivaroxaban: Insights from the ONCO PE trial.

A systematically derived risk model for 3-year all-cause mortality after acute venous thromboembolism.

A systematically derived risk model for 3-year all-cause mortality after acute venous thromboembolism.

Utility of simplified PESI score for mid-term mortality risk stratification: Insights from the combined COMMAND-VTE registries.

Utility of simplified PESI score for mid-term mortality risk stratification: Insights from the combined COMMAND-VTE registries.

Associations between heart failure-related quality of life and clinical parameters in patients with hypertrophic cardiomyopathy: a cross-sectional analysis of data from a multicentre Japanese registry.

Associations between heart failure-related quality of life and clinical parameters in patients with hypertrophic cardiomyopathy: a cross-sectional analysis of data from a multicentre Japanese registry.

Impact of stricter lipid control on cardiovascular outcomes in a regional hospital-clinic referral system.

Impact of stricter lipid control on cardiovascular outcomes in a regional hospital-clinic referral system.

Clinical Outcomes of Anticoagulation Therapy With Direct Oral Anticoagulants or Warfarin in Patients With Atrial Fibrillation and Renal Impairment After Bioprosthetic Valve Replacement.

Clinical Outcomes of Anticoagulation Therapy With Direct Oral Anticoagulants or Warfarin in Patients With Atrial Fibrillation and Renal Impairment After Bioprosthetic Valve Replacement.

Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).

Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).

Bioprosthetic Valve Positions in Patients With Atrial Fibrillation - Insights From the BPV-AF Registry.

Bioprosthetic Valve Positions in Patients With Atrial Fibrillation - Insights From the BPV-AF Registry.

CORRIGENDUM: Antithrombotic Therapy for Patients With Atrial Fibrillation and Bioprosthetic Valves - Real-World Data From the Multicenter, Prospective, Observational BPV-AF Registry.

CORRIGENDUM: Antithrombotic Therapy for Patients With Atrial Fibrillation and Bioprosthetic Valves - Real-World Data From the Multicenter, Prospective, Observational BPV-AF Registry.

Long-Term Effects of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention in High-Risk Subgroups.

Long-Term Effects of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention in High-Risk Subgroups.

R2-CHA2DS2-VASc Score for Cardiovascular Event Prediction After Bioprosthetic Valve Replacement - Subanalysis From the BPV-AF Registry.

R2-CHA2DS2-VASc Score for Cardiovascular Event Prediction After Bioprosthetic Valve Replacement - Subanalysis From the BPV-AF Registry.

Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism - A Predetermined Companion Report From the ONCO PE Trial.

Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism - A Predetermined Companion Report From the ONCO PE Trial.

Bioprosthetic Valve Positions in Patients With Atrial Fibrillation　- Insights From the BPV-AF Registry.

Bioprosthetic Valve Positions in Patients With Atrial Fibrillation　- Insights From the BPV-AF Registry.

CORRIGENDUM: Antithrombotic Therapy for Patients With Atrial Fibrillation and Bioprosthetic Valves　- Real-World Data From the Multicenter, Prospective, Observational BPV-AF Registry.

CORRIGENDUM: Antithrombotic Therapy for Patients With Atrial Fibrillation and Bioprosthetic Valves　- Real-World Data From the Multicenter, Prospective, Observational BPV-AF Registry.

R2-CHA2DS2-VASc Score for Cardiovascular Event Prediction After Bioprosthetic Valve Replacement　- Subanalysis From the BPV-AF Registry.

R2-CHA2DS2-VASc Score for Cardiovascular Event Prediction After Bioprosthetic Valve Replacement　- Subanalysis From the BPV-AF Registry.

Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism　- A Predetermined Companion Report From the ONCO PE Trial.

Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism　- A Predetermined Companion Report From the ONCO PE Trial.